Fenwick & West represented Mavupharma, Inc., a drug discovery and development company focused on non-nucleotide modulators of the STING pathway to treat cancer and infectious diseases, in its $20 million Series A funding. Frazier Healthcare Partners led the round with participation from Alpine BioVentures.
Mavu will use the funds to advance its drug candidates into the clinic. More information about Mavu’s $20 million Series A financing can be obtained from the company announcement.
The Fenwick transaction team was led by corporate lawyers Matt Rossiter, Katherine Duncan, Liz Federowicz and Daniel Renz.